Nabsys and Dr. Martin Taylor’s Lab at Brown University Present Data Using OhmX™ Platform at AGBT 2026
Providence, Rhode Island, February 25, 2026 /PRNewswire/ — Nabsys 2.0, LLC (Nabsys), a pioneer in electronic genome mapping (EGM) technology, today announced new discoveries presented at the Advances in Genome Biology and Technology (AGBT) 2026 conference. The data is presented in a poster titled “.Genome-scale direct mapping of the endonuclease activity of the human LINE-1 ORF2p endonuclease” (Poster 439), presented by the research team of Dr. Martin Taylor, assistant professor of pathology and laboratory medicine at Brown University.
EGM enables direct detection of endonuclease activity at the genome scale by identifying DNA nicking events on long DNA molecules. This feature addresses the challenges associated with mapping endonuclease-induced nicks within complex DNA mixtures. Beyond endonuclease activity, future applications of EGM may enable direct genome-wide analysis of additional DNA modifications and lesions.
The data presented demonstrate the use of EGM to directly measure nick positions generated by the LINE-1 ORF2p endonuclease throughout the human genome. This approach allows sequence-level insight into the endonuclease activity associated with the LINE-1 retrotransposon that causes DNA damage and mutations in the human genome.
LINE-1 is an autonomous retrotransposon that expands within the genome through an RNA-mediated “copy-and-paste” mechanism, writing approximately one-third of the human genome. Approximately 5% of humans carry new LINE-1-mediated genomic insertions that are not present in either parent. ORF2p activity is increasingly recognized to contribute to genomic instability, particularly in cancer, by generating DNA breaks that can lead to insertions and structural rearrangements. Aberrant LINE-1 activity is also associated with neurodegenerative diseases and age-related functional decline, highlighting the importance of mapping its activity genome-wide.
“Our understanding of the genomic sequence of LINE-1 endonuclease cleavage is limited,” said Dr. Martin Taylor, principal investigator of the study. “Understanding this activity is important for understanding LINE-1-mediated DNA damage in cancer and insertional mutagenesis in sporadic genetic diseases. EGM provides a powerful tool to directly map this important enzyme activity genome-wide. We are also very excited about the potential application of EGM to other assays, such as directly mapping other DNA modifications and binding events.”
To perform the assay, ORF2p endonuclease-treated DNA molecules were labeled using the OhmX Velocity Optimized Label and Tagging™ (“VOLT”) Whole Genome Kit. The prepared samples were then analyzed using EGM on the OhmX™ platform to identify and map endonuclease nick sites. To determine endonuclease activity, we evaluated the nicking frequency in a concentration-dependent manner.
“LINE-1 activity contributes to the pathology of common diseases such as cancer by inducing inflammation and DNA damage,” said Barrett Brady, MD, founder and CEO of Nabsys. “We are pleased to collaborate with Marty Taylor and his team on this important research. We believe EGM is a powerful tool for directly measuring genome-scale DNA modifications and has the potential to have a major impact on the discovery and development of cell and gene therapies.”
About Nabsys 2.0, LLC
Nabsys advances genomics through its proprietary electronic genome mapping (EGM) technology with a clear focus on accessibility and innovation. EGM implemented on the OhmX™ platform integrates precision electronics, nanofluidics, and computational biology to provide high-resolution insights into genome structure. This approach expands what is possible in cytogenetics, molecular genetics, and cell and gene therapy research, while providing comprehensive structural variation analysis for laboratories of all sizes. The company was founded in 2005 and is based in Providence, Rhode Island. For more information, please visit: www.nabsys.com.
media contact
David Rosen
Argot Partners
David.rosen@argotpartners.com
646-461-6387
Logo – https://mma.prnasia.com/media2/1859848/Nabsys_Logo.jpg?p=medium600
| This article was produced by our trusted news partner, Cision PR Newswire. The views and content expressed herein are solely those of the author and may not fully reflect the views of Thai Business News. |
Read the original article: Genome-scale direct mapping of the endonuclease activity of the human LINE-1 ORF2p endonuclease